Treatment of hepatitis C virus infection: Is it time for the internist to take the reins?

Annals of Internal Medicine

Volumn 161, Issue 6, 2014, Pages 443-444

  Kottilil, Shyam ^a   Wright, Mary ^a   Polis, Michael A ^a   Masur, Henry ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEPATITIS C; HUMAN; INTERNIST; NOTE; PATIENT CARE; PATIENT COUNSELING; TREATMENT OUTCOME; ARTICLE; INTERNAL MEDICINE; PHYSICIAN ATTITUDE;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERNAL MEDICINE; PHYSICIAN'S ROLE;

EID: 84907209968     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0741     Document Type: Note

References (10)

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014; 160:293-300. [PMID: 24737271] doi:10.7326/M13-1133
2. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013; 19:850-8. [PMID: 23836235] doi:10.1038/nm.3184
3. Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2013. [PMID: 24164865] doi: 10.1111/liv.12370
4. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013; 57:1325-32. [PMID: 23315914] doi:10.1002/hep. 26246
5. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368:1878-87. [PMID: 23607594] doi:10.1056/NEJMoa1214853
6. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370:211-21. [PMID: 24428467] doi:10.1056/NEJMoa1306218
7. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, et al. Directly acting triple-drug anti-HCV therapy induces complete virologic response with a six-week regimen: a proof of concept phase 2a cohort study. Lancet. 2014. [Forthcoming].
8. Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011; 364:2199-207. [PMID: 21631316] doi:10.1056/NEJMoa1009370
9. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013; 57:1164-71. [PMID: 23797289] doi:10.1093/cid/cit420
10. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success [Editorial]. N Engl J Med. 2014; 370:1552-3. [PMID: 24725236] doi:10.1056/NEJMe1401508